Compagnie Lombard Odier SCmA
KITE

Compagnie Lombard Odier SCmA’s Kite Pharma, Inc. KITE Stock Holding History

Compagnie Lombard Odier SCmA’s Portfolio KITE Stock Details KITE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-6,000
Closed -$269K – 889
2016
Q4 		$269K Sell
6,000
-2,000
-25% -$98.1K 0.01% 403
2016
Q3 		$447K Hold
8,000
– – 0.01% 370
2016
Q2 		$400K Hold
8,000
– – 0.01% 374
2016
Q1 		$367K Hold
8,000
– – 0.01% 393
2015
Q4 		$493K Buy
+8,000
New +$563K 0.02% 322

Other funds holding KITE

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WCM
Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Compagnie Lombard Odier SCmA's KITE Position: Q1 2017 in Review

Compagnie Lombard Odier SCmA sold out of Kite Pharma, Inc. (KITE) in Q1 2017, closing a stake of 6,000 shares — an estimated $269K sold.

Compagnie Lombard Odier SCmA first reported a position in KITE in Q4 2015 and held it in 5 quarters. The position peaked at $493K in Q4 2015. 209 funds tracked by Wall St. Rank hold KITE as of Q1 2017.

  • Compagnie Lombard Odier SCmA reported no remaining Kite Pharma, Inc. position as of Q1 2017 after selling out during the quarter.
  • Compagnie Lombard Odier SCmA sold 6,000 Kite Pharma, Inc. shares in Q1 2017, an estimated $269K.
  • Compagnie Lombard Odier SCmA first reported a position in Kite Pharma, Inc. in Q4 2015 and held it in 5 quarters.
  • Compagnie Lombard Odier SCmA's Kite Pharma, Inc. position peaked at $493K in Q4 2015.
  • 209 funds tracked by Wall St. Rank held Kite Pharma, Inc. as of Q1 2017.

Based on Compagnie Lombard Odier SCmA's 13F filing for Q1 2017, filed 15 May 2017.